Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers

US8999390B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Holger Petersen · Pastetten, DE
• Markus Ahlheim · Staufen, DE

Key dates

• Filing date: May 15, 2012
• Grant date: Apr 7, 2015
• Expiry date: Dec 2, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).